Anders: Celebrex, Abilify Price Drops Trigger MSA Reductions
Tuesday, December 15, 2020 | 0
Recently, the lowest average wholesale price of 200 milligram Celebrex and the price of multiple strengths of Abilify dropped dramatically, resulting in major cost savings to Medicare set-aside allocations.
A widely used, non-steroidal anti-inflammatory drug, Celebrex (Celecoxib), is FDA-approved for several conditions:
- Ankylosing spondylitis.
- Juvenile rheumatoid arthritis.
- Acute migraine.
- Acute pain.
- Primary dysmenorrhea.
- Rheumatoid arthritis.
Per Red Book, the lowest average wholesale price for 200 milligram Celecoxib dropped from $1.79 to $0.33, an 81.56% reduction.
Abilify (Aripiprazole) is an antipsychotic drug FDA-approved for the following conditions:
- Acute treatment of manic and mixed episodes associated with bipolar disorder.
- Adjunctive treatment of major depressive disorder.
- Irritability associated with autistic disorder.
- Treatment of Tourette’s disorder.
Per Red Book, the lowest average wholesale price for multiple strengths (2 milligrams to 30 milligrams) of Aripiprazole dropped from the $30 to $36 range to a range of $0.07 to $0.17 per dose, an almost 100% price reduction.
Because Tower’s system tracks all medications allocated in MSA reports, we have already pulled reports from the past two years that allocated these medications and advised clients of the potential for a reduction. You can also contact us to determine whether a particular MSA qualifies for a reduction. Revisions to the MSA can be done now or prior to MSA submission to the Centers for Medicare and Medicaid.
Dan Anders is chief compliance officer at Tower MSA Partners LLC. This entry is republished with permission from the Tower MSP Compliance Blog.